245 related articles for article (PubMed ID: 17932894)
1. A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: a Children's Oncology Group study.
Fouladi M; Nicholson HS; Zhou T; Laningham F; Helton KJ; Holmes E; Cohen K; Speights RA; Wright J; Pollack IF;
Cancer; 2007 Dec; 110(11):2535-41. PubMed ID: 17932894
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: a pediatric brain tumor consortium study.
Fouladi M; Blaney SM; Poussaint TY; Freeman BB; McLendon R; Fuller C; Adesina AM; Hancock ML; Danks MK; Stewart C; Boyett JM; Gajjar A
Cancer; 2006 Nov; 107(9):2291-7. PubMed ID: 17019740
[TBL] [Abstract][Full Text] [Related]
3. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Nicholson HS; Kretschmar CS; Krailo M; Bernstein M; Kadota R; Fort D; Friedman H; Harris MB; Tedeschi-Blok N; Mazewski C; Sato J; Reaman GH
Cancer; 2007 Oct; 110(7):1542-50. PubMed ID: 17705175
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma.
Haas-Kogan DA; Banerjee A; Kocak M; Prados MD; Geyer JR; Fouladi M; McKnight T; Poussaint TY; Broniscer A; Blaney SM; Boyett JM; Kun LE
Neuro Oncol; 2008 Jun; 10(3):341-7. PubMed ID: 18417739
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
Cloughesy TF; Wen PY; Robins HI; Chang SM; Groves MD; Fink KL; Junck L; Schiff D; Abrey L; Gilbert MR; Lieberman F; Kuhn J; DeAngelis LM; Mehta M; Raizer JJ; Yung WK; Aldape K; Wright J; Lamborn KR; Prados MD
J Clin Oncol; 2006 Aug; 24(22):3651-6. PubMed ID: 16877733
[TBL] [Abstract][Full Text] [Related]
6. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.
Gururangan S; Chi SN; Young Poussaint T; Onar-Thomas A; Gilbertson RJ; Vajapeyam S; Friedman HS; Packer RJ; Rood BN; Boyett JM; Kun LE
J Clin Oncol; 2010 Jun; 28(18):3069-75. PubMed ID: 20479404
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study.
Warren KE; Gururangan S; Geyer JR; McLendon RE; Poussaint TY; Wallace D; Balis FM; Berg SL; Packer RJ; Goldman S; Minturn JE; Pollack IF; Boyett JM; Kun LE
J Neurooncol; 2012 Feb; 106(3):643-9. PubMed ID: 21968943
[TBL] [Abstract][Full Text] [Related]
8. A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study.
Fouladi M; Stewart CF; Blaney SM; Onar-Thomas A; Schaiquevich P; Packer RJ; Goldman S; Geyer JR; Gajjar A; Kun LE; Boyett JM; Gilbertson RJ
J Neurooncol; 2013 Sep; 114(2):173-9. PubMed ID: 23836190
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience.
Turner CD; Gururangan S; Eastwood J; Bottom K; Watral M; Beason R; McLendon RE; Friedman AH; Tourt-Uhlig S; Miller LL; Friedman HS
Neuro Oncol; 2002 Apr; 4(2):102-8. PubMed ID: 11916501
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study.
Hurwitz CA; Strauss LC; Kepner J; Kretschmar C; Harris MB; Friedman H; Kun L; Kadota R
J Pediatr Hematol Oncol; 2001; 23(5):277-81. PubMed ID: 11464982
[TBL] [Abstract][Full Text] [Related]
11. A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study.
Salloum R; Hummel TR; Kumar SS; Dorris K; Li S; Lin T; Daryani VM; Stewart CF; Miles L; Poussaint TY; Stevenson C; Goldman S; Dhall G; Packer R; Fisher P; Pollack IF; Fouladi M; Boyett J; Drissi R
J Neurooncol; 2016 Sep; 129(3):443-451. PubMed ID: 27350411
[TBL] [Abstract][Full Text] [Related]
12. Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study.
Hawkins DS; Bradfield S; Whitlock JA; Krailo M; Franklin J; Blaney SM; Adamson PC; Reaman G
Pediatr Blood Cancer; 2006 Nov; 47(6):790-4. PubMed ID: 16435380
[TBL] [Abstract][Full Text] [Related]
13. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.
Fangusaro J; Onar-Thomas A; Young Poussaint T; Wu S; Ligon AH; Lindeman N; Banerjee A; Packer RJ; Kilburn LB; Goldman S; Pollack IF; Qaddoumi I; Jakacki RI; Fisher PG; Dhall G; Baxter P; Kreissman SG; Stewart CF; Jones DTW; Pfister SM; Vezina G; Stern JS; Panigrahy A; Patay Z; Tamrazi B; Jones JY; Haque SS; Enterline DS; Cha S; Fisher MJ; Doyle LA; Smith M; Dunkel IJ; Fouladi M
Lancet Oncol; 2019 Jul; 20(7):1011-1022. PubMed ID: 31151904
[TBL] [Abstract][Full Text] [Related]
14. Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021.
Wetmore C; Daryani VM; Billups CA; Boyett JM; Leary S; Tanos R; Goldsmith KC; Stewart CF; Blaney SM; Gajjar A
Cancer Med; 2016 Jul; 5(7):1416-24. PubMed ID: 27109549
[TBL] [Abstract][Full Text] [Related]
15. Primitive neuroectodermal tumors of the brainstem in children treated according to the HIT trials: clinical findings of a rare disease.
Friedrich C; Warmuth-Metz M; von Bueren AO; Nowak J; Bison B; von Hoff K; Pietsch T; Kortmann RD; Rutkowski S
J Neurosurg Pediatr; 2015 Mar; 15(3):227-35. PubMed ID: 25555122
[TBL] [Abstract][Full Text] [Related]
16. Phase II evaluation of topotecan for pediatric central nervous system tumors.
Blaney SM; Phillips PC; Packer RJ; Heideman RL; Berg SL; Adamson PC; Allen JC; Sallan SE; Jakacki RI; Lange BJ; Reaman GH; Horowitz ME; Poplack DG; Balis FM
Cancer; 1996 Aug; 78(3):527-31. PubMed ID: 8697400
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children's Oncology Group.
Warren K; Jakacki R; Widemann B; Aikin A; Libucha M; Packer R; Vezina G; Reaman G; Shaw D; Krailo M; Osborne C; Cehelsky J; Caldwell D; Stanwood J; Steinberg SM; Balis FM
Cancer Chemother Pharmacol; 2006 Sep; 58(3):343-7. PubMed ID: 16408203
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of temozolomide and topotecan (TOTEM) in children with relapsed or refractory extracranial and central nervous system tumors including medulloblastoma with post hoc Bayesian analysis: A European ITCC study.
Le Teuff G; Castaneda-Heredia A; Dufour C; Jaspan T; Calmon R; Devos A; McHugh K; Leblond P; Frappaz D; Aerts I; Zwaan CM; Ducassou S; Chastagner P; Verschuur A; Corradini N; Casanova M; Rubie H; Riccardi R; Le Deley MC; Vassal G; Geoerger B;
Pediatr Blood Cancer; 2020 Jan; 67(1):e28032. PubMed ID: 31595663
[TBL] [Abstract][Full Text] [Related]
19. Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hematology.
Wagner S; Erdlenbruch B; Längler A; Gnekow A; Kühl J; Albani M; Völpel S; Bucsky P; Emser A; Peters O; Wolff JE
Cancer; 2004 Apr; 100(8):1750-7. PubMed ID: 15073866
[TBL] [Abstract][Full Text] [Related]
20. Prolonged use of nimotuzumab in children with central nervous system tumors: safety and feasibility.
Cabanas R; Saurez G; Alert J; Reyes A; Valdes J; Gonzalez MC; Pedrayes JL; Valle L; Infante M; Avila M; Herrera R; Hechavarria E; Rios M; Fernández A; Lorenzo Luaces P; Crombet Ramos T
Cancer Biother Radiopharm; 2014 May; 29(4):173-8. PubMed ID: 24784755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]